Clinical trial · Interventional
PET and MRI Imaging of Brain Tumors Using [18F]PARPi
Pilot Study of [18F]PARPi PET/MR Imaging in Patients With New and/or Suspected Recurrent Brain Tumors
NCT04173104CI-TRIAL-00102756completedEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to collect data about how 18FPARPi can be used together with PET/positron emission tomography and MRI/magnetic resonance imaging scans to take pictures of brain cancer
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Cancer | Malignant Brain Neoplasm | ALIAS | 0.90 |
| Brain Tumor | Brain Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [18F]PARPi | Drug | — | UNRESOLVED |
| PET/MR with [18F]PARPi | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Participants with Brain Cancer
- description
- Participants with new or suspected recurrent brain tumors
- interventionNames
- Diagnostic Test: PET/MR with [18F]PARPi
- Drug: [18F]PARPi
Primary outcomes (1)
- measure
- SUVmax measurements
- timeFrame
- Up to 24 weeks
- description
- \[18F\]PARPi updtake in lesions will be quantified by standard SUVmax measurements from PET/MR scans
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with new or suspected recurrent brain tumors (including suspected recurrent brain tumors showing growth from any preceding scan) * Age \>/= 18 years * Minimum at least one brain lesion size \>/= 1.5cm diameter * Scheduled to undergo treatment at MSK * Willingness to sign informed consent * Able to receive intravenous gadolinium contrast per MSK Department of Radiology guidelines Exclusion Criteria: * Any contraindication to 3T MRI (PET/MR scanner is 4.0 Tesla) * Pregnancy or breast-feeding women
References
Publications (0)
Data not yet available
No reference posted for this study.